Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations

prnasiaMarch 25, 2020

Tag: Merck , TEPMETKO , NSCLC

PharmaSources Customer Service